134594-22-2

Upstream product

• 61735-51-1 1-iodo-5-methoxynaphthalene 
• 68-12-2 N,N-dimethyl-formamide 
• 3813-01-2 1-cyano-5-methoxynaphthalene 
• 135678-23-8 2-Bromo-3-methoxyphenyl Toluene-p-sulphonate 
• 150-19-6 O-methylresorcine 
• 135999-38-1 2-(5-Methoxynaphthalen-1-yl)-1,3-dioxolane 
• 135999-16-5 2-Bromo-3-methoxyphennol 
• 30778-86-0 1-methoxy-3-tetrahydropyran-2-yloxybenzene 

Downstream Products

• 144876-33-5 5-hydroxy-1-naphthaldehyde 

Relevant academic research and scientific papers

BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu- opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor

There is still a need for additional scaffolds to further explore tissue selectivity and improving efficacy of selective estrogen receptor modulators (SERMs). A series of hydroxyl substituted diphenylnaphthyl alkene ligands for the two estrogen receptors are described that arose from an initial de novo designed diphenylnaphthyl propylene ligand 1. All compounds gave Kis under 10 nM when assayed in the presence of ERα. Generally these compounds had very high affinity for both ER isotypes. Moving the hydroxyl group on naphthalene from the 6- to the 5-position of the α-naphthalene attached compounds (6b and 6e vs 6c and 6f) had little affect on ER binding nor did altering the position of the naphthalene attachment (α or β) to the alkene moiety. In transfection assays none of the compounds displayed agonistic activity in the absence of E2. In MCF-7 proliferation assays 6a-d, 6f and 12a-c successfully abrogated E2 stimulation and resulted in greater than 50% inhibition at 1 μM, a level of efficacy similar to that obtained when the cells were treated with raloxifene. Our results show that this new class of SERMs are good candidates for further study as therapeutic agents for the treatment of breast cancer and osteoporosis.

Regioselectivity in the Reactions of Methoxydehydrobenzenes with Furans. Part 1. Reactions of 3-Methoxydehydrobenzene and 3-(Methoxycarbonyl)dehydrobenzene with 2-Substituted Furans.

The isomer ratios for the cycloadducts obtained for the reaction of 3-methoxydehydrobenzene, generated from 2-amino-6-methoxybenzoic acid by aprotic diazotization, or from 2-bromo-3-methoxyphenyl toluene-p-sulphonate by treatment with butyllithium, and fo